Sharon Bio-Medicine Peer Comparison

NSE: SHARONBIO | BSE: 532908

₹3.30

₹-0.15 (-4.35%)

As on 28-Mar-2019IST

Market cap

₹2 Cr

Revenue (TTM)

₹240 Cr

P/E Ratio

0.1

P/B Ratio

-0.1

Div. Yield

0 %

Edit

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2	30,951	30,239	28,444	25,690
Revenue (₹ Cr)	240	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	41.01	414.00	288.22	-371.81	387.35
Net Margin (%)	16.28	11.23	14.79	-3.93	26.01
RoE (%)	58.92	8.38	29.77	-3.85	25.18
Price to Earnings	0.10	75.67	104.92	--	66.52
Price-To-Book	-0.06	6.15	22.53	3.55	14.89

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	240.45	3,373.00	1,753.96	8,869.08	1,339.37
Total Income	251.96	3,510.00	1,762.66	9,111.51	1,380.95
Total Expenditure	181.22	2,747.00	1,354.69	7,976.59	858.97
EBITDA	59.23	626.00	399.26	892.49	480.40
Depreciation	7.85	227.00	45.26	831.24	35.99
EBIT	51.38	399.00	354.00	61.25	444.41
Interest	8.93	213.00	42.17	340.80	3.27
Other Income	11.50	137.00	8.70	242.43	41.59
Exceptional Items	--	-85.00	--	-196.14	--
Profit before Tax	53.95	238.00	320.53	-176.06	482.73
Provision for Tax	12.94	39.00	73.80	149.88	126.36
Profit after Tax	41.01	199.00	246.74	-325.94	356.37

Liabilities (₹ Cr)

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	90.38	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	--	341.00	0.00	--	57.19
Non-Current Liabilities	39.03	1,235.00	189.02	4,529.41	42.40
Current Liabilities	85.14	1,622.00	835.87	4,874.74	230.81
Total Liabilities	214.55	8,578.00	2,326.71	17,723.32	1,983.96

Assets (₹ Cr)

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	110.04	5,441.00	631.90	10,258.66	1,102.69
Current Assets	104.52	2,606.00	1,681.81	7,308.11	881.27
Total Assets	214.55	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	86.39	2,125.00	259.37	5,495.48	26.49
Net Current Assets	19.38	984.00	845.94	2,433.37	650.46
Contingent Liabilities	1.67	768.26	19.09	95.72	17.25

Cashflow (₹ Cr)

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	45.06	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	1.05	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	-45.18	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	0.93	95.00	78.39	787.59	30.33

Ratios

Profitability Ratios

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	36.08	6.79	29.22	1.24	32.42
ROE (%)	58.92	4.29	27.84	-4.04	24.08
ROA (%)	19.68	2.53	13.11	-1.98	20.17
EBIT Margin (%)	29.42	22.62	23.26	12.80	38.97
Net Margin (%)	16.28	5.67	14.00	-3.58	25.81
Cash Profit Margin (%)	20.32	10.98	7.71	4.80	29.29

Growth Ratios

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	21.76	11.99	36.57	-3.08	33.02
EBIT Growth (%)	37.69	67.69	52.29	-28.15	109.63
Net Profit Growth (%)	76.94	449.12	83.64	-457.66	122.15
EPS Growth (%)	76.94	553.20	71.44	-456.91	348.92
Book Value Growth (%)	85.09	13.47	144.31	0.33	26.03

Valuation Ratios

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	89.54	51.69	0.00	58.79
Price / Book Value	0.00	3.87	10.14	2.24	12.69
Dividend Yield (%)	--	0.00	0.19	0.00	0.10
EV/EBITDA	1.21	27.45	31.05	19.72	39.75
Market Cap (₹ Cr)	0.00	19,071.62	12,753.19	18,108.89	20,944.75

Solvency Ratios

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.96	0.43	0.21	0.68	0.02
Short term debt to equity ratio	0.25	0.09	0.05	0.09	0.02
Current Ratio	1.23	1.61	2.01	1.50	3.82
Quick Ratio	0.74	1.06	1.14	0.87	2.82
Interest Coverage	7.04	2.12	8.60	0.48	148.71

Operating Efficiency Ratios

	Sharon Bio-Medicine	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	21.27	17.43	29.00	24.33	27.07
Asset Turnover	1.15	0.49	2.01	0.64	0.76
Receivable days	69.26	58.75	40.13	78.20	88.98
Inventory Days	58.25	75.82	60.29	93.30	56.04
Payable days	85.50	186.21	232.47	226.14	99.95
Cash Conversion Cycle	42.01	-51.64	-132.04	-54.64	45.07